The patients were randomly assigned 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily.
The investigators performed univariate and multivariate analyses to identify factors associated with the loss of MMR.
From 2017 to 2019, the number of beneficiaries prescribed at least 1 oral TKI increased from 154 beneficiaries to 212 beneficiaries.
Investigators reported findings from the ongoing SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) study.
In CML, second malignancies are rare and trends remain poorly understood.
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?
The underlying mechanisms of late recurrence must be investigated further, according to researchers.
Overall survival data were available for about half of the drugs.
Updated data demonstrated asciminib significantly improved the rate of MMR at 48 weeks compared with bosutinib.
Seroconversion was observed in 99% of patients with chronic myeloid leukemia.
A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.
Patients’ age, sex, and treatment-related symptoms, as well as mothers’ education level, were significantly associated with HRQOL.
Researchers sought to determine whether there was a difference in generic or branded imatinib in treating patients with CML.
Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket.
Researchers sought to determine the accuracy of established tools in predicting the risk of cardiovascular events in patients with CML receiving TKIs.
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.